10-K: Xenetic Biosciences Reports 2024 Annual Results, Focuses on DNase Technology

Xenetic Biosciences' 2024 10-K filing highlights the company's focus on advancing its DNase technology for cancer treatment amid ongoing financial losses.

Summary

• Xenetic Biosciences, a biopharmaceutical company, reported its 10-K filing for the fiscal year ended December 31, 2024.
• The company is focused on advancing its DNase technology for treating difficult-to-treat cancers.
• Xenetic is targeting neutrophil extracellular traps (NETs) to improve outcomes of existing cancer treatments.
• The company's systemic DNase program is initially targeting pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC), and other gastrointestinal cancers.
• Xenetic is also conducting pre-clinical research with the goal of demonstrating that armoring CAR T cells to secrete DNase can support depth and durability of response against solid tumor indications.
• The company has collaborations with Volition SARL Limited, Scripps Research Institute, and the University of Virginia to advance its technologies.
• Xenetic receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders related to its PolyXen platform.
• The company reported royalty revenue of approximately $2.5 million for both 2024 and 2023.
• Xenetic had an accumulated deficit of approximately $197.2 million as of December 31, 2024.
• The company expects to incur additional operating losses as it expands its research and development activities.
• Xenetic had cash of approximately $6.2 million as of December 31, 2024.
• The company will require substantial additional funding to achieve its goals.
• The company is dependent on the success of the DNase technology.
• Xenetic relies on contract manufacturers, CROs, and strategic collaborations to manage its overhead.
• The company is subject to numerous risks, including the uncertainty of achieving profitability, the need for additional funding, and the competitive environment.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is making progress in its research and development efforts, it is also facing significant financial challenges and risks.

Positives

• The company is focused on advancing its DNase technology for cancer treatment.
• The company has collaborations with UVA and Scripps Research to advance the development of its systemic DNase program.
• The company is conducting pre-clinical research with the goal of demonstrating that armoring CAR T cells to secrete DNase can support depth and durability of response against solid tumor indications.
• The company reported royalty revenue of approximately $2.5 million for both 2024 and 2023 from its PolyXen technology.

Negatives

• Xenetic had an accumulated deficit of approximately $197.2 million as of December 31, 2024.
• The company expects to incur additional operating losses as it expands its research and development activities.
• The company will require substantial additional funding to achieve its goals.
• The company is dependent on the success of the DNase technology.

Risks

• The company may never achieve or sustain profitability.
• The company will require substantial additional funding to achieve its goals.
• Raising additional capital may cause dilution to stockholders.
• The company may not continue to meet the continued listing requirements of the Nasdaq Stock Market.
• The company's business is substantially dependent on the success of the DNase technology.
• The company operates in an extremely competitive environment.
• The company is an early-stage company in the business of developing pharmaceutical products.
• Conflicts may arise between the company and its collaborators or strategic partners.
• The company expects to rely on third parties to conduct clinical studies.
• The company may find it difficult to enroll patients in its clinical studies.
• The company may encounter substantial delays in commencement, enrollment or completion of its clinical trials.
• The company may not be successful in its efforts to identify or discover additional pharmaceutical products.
• The market opportunities for the company's drug candidates may be limited and small.
• The company has no manufacturing, sales, marketing or distribution capabilities.
• The company's reliance on third parties requires it to share its trade secrets.
• The company may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The market price of the company's securities may be highly volatile.
• Actions of activist shareholders could cause the company to incur substantial costs and divert management's attention.
• The company's preferred stockholders have rights, preferences and privileges that are not held by, and are preferential to, the rights of its common stockholders.

Future Outlook

Xenetic expects to continue to incur significant operating losses as it expands its research and development activities and anticipates needing additional capital to pursue its business initiatives.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Xenetic faces potential competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention some of the competitors in the pancreatic cancer and solid tumor treatment space.
• For pancreatic cancer, competitors include companies developing treatments based on Gemcitabine, Abraxane, FOLFIRINOX, and Onivyde.
• For CRC, competitors include companies developing treatments based on fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, aflibercept, ramucirumab, trastuzumab, and encorafenib-cetuximab.

Management Changes

Related Party Transactions

• The company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez, each a related party.
• One of the company's directors, Dr. Dmitry Genkin, is a significant shareholder of PeriNess Ltd., and another of the company's directors, Mr. Moshe Mizrahy, is a majority shareholder and director of PeriNess.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by changes in the company's strategy and operations.
• Customers (potential patients) may benefit from the development of new cancer treatments.
• Suppliers and creditors may be affected by the company's financial condition.

Next Steps

• The company intends to pursue orphan drug designations and accelerated approval pathways for relevant oncology indications as appropriate in both the U.S. and Europe.
• The company intends to advance development of its DNase technology primarily through the use of contract manufacturing, contract research organizations (CROs) and academic institutions in order to efficiently manage its resources.

Key Dates